Skip to main content
Article thumbnail
Location of Repository

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

By Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren, Lennart Holm, Jonatan Lindh, Anders Rane, Mia Wadelius and Panos Deloukas


We report the first genome-wide association study (GWAS) whose sample size (1,053 Swedish subjects) is sufficiently powered to detect genome-wide significance (p<1.5×10−7) for polymorphisms that modestly alter therapeutic warfarin dose. The anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonary embolism, and coronary malfunction. However, Caucasians vary widely (20-fold) in the dose needed for therapeutic anticoagulation, and hence prescribed doses may be too low (risking serious illness) or too high (risking severe bleeding). Prior work established that ∼30% of the dose variance is explained by single nucleotide polymorphisms (SNPs) in the warfarin drug target VKORC1 and another ∼12% by two non-synonymous SNPs (*2, *3) in the cytochrome P450 warfarin-metabolizing gene CYP2C9. We initially tested each of 325,997 GWAS SNPs for association with warfarin dose by univariate regression and found the strongest statistical signals (p<10−78) at SNPs clustering near VKORC1 and the second lowest p-values (p<10−31) emanating from CYP2C9. No other SNPs approached genome-wide significance. To enhance detection of weaker effects, we conducted multiple regression adjusting for known influences on warfarin dose (VKORC1, CYP2C9, age, gender) and identified a single SNP (rs2108622) with genome-wide significance (p = 8.3×10−10) that alters protein coding of the CYP4F2 gene. We confirmed this result in 588 additional Swedish patients (p<0.0029) and, during our investigation, a second group provided independent confirmation from a scan of warfarin-metabolizing genes. We also thoroughly investigated copy number variations, haplotypes, and imputed SNPs, but found no additional highly significant warfarin associations. We present power analysis of our GWAS that is generalizable to other studies, and conclude we had 80% power to detect genome-wide significance for common causative variants or markers explaining at least 1.5% of dose variance. These GWAS results provide further impetus for conducting large-scale trials assessing patient benefit from genotype-based forecasting of warfarin dose

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008). A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
  2. (2005). A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
  3. (2006). A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
  4. (2008). A robust statistical method for case-control association testing with copy number variation.
  5. (2007). A second generation human haplotype map of over 3.1 million SNPs.
  6. (1992). A simple regression method for mapping quantitative trait loci in line crosses using flanking markers.
  7. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
  8. (2007). Association of warfarin dose with genes involved in its action and metabolism.
  9. (2004). Bounds and normalization of the composite disequilibrium coefficient. Genetic Epidemiology 271: 252–257.
  10. (2007). Breaking the waves: improved detection of copy number variation from microarray-based comparative genomic hybridization.
  11. (2004). Circular binary segmentation for the analysis of array-based DNA copy number data.
  12. (2005). Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
  13. (2008). CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
  14. (2008). CYP4F2 genetic variant alters required warfarin dose.
  15. (2004). Detection of large-scale variation in the human genome.
  16. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
  17. (2008). Estimating coverage and power for genetic association studies using near-complete variation data.
  18. (1996). Genetic analysis of the human cytochrome P450 CYP2C9 locus.
  19. (1996). Genetic Data Analysis II.
  20. (2008). Genetic testing for warfarin therapy initiation.
  21. (2006). Highresolution genomic profiling of chromosomal aberrations using Infinium wholegenome genotyping.
  22. (1979). Inferences about linkage disequilibrium.
  23. (1993). Interval mapping of multiple quantitative trait loci.
  24. (1999). Kendall’s advanced theory of statistics. London:
  25. (2008). Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.
  26. (2001). Linkage disequilibrium in humans: models and data.
  27. (2000). Mathematical statistics. Boca Raton:
  28. (2003). Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.
  29. (2003). Pharmacogenetics of oral anticoagulants.
  30. (2005). Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
  31. (2007). Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
  32. (2004). Rane A
  33. (2007). Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering.
  34. (2009). The largest prospective warfarin-treated cohort supports genetic forecasting.
  35. (2006). The pharmocogenomics of warfarin: closing in on personalized medicine.
  36. (2008). To what extent do scans of nonsynonymous SNPs complement denser genome-wide association studies?
  37. (2008). Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
  38. (2008). Warfarin Pharmacogenetics.
  39. (2004). Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
  40. (2007). Wellcome Trust Case Control Consortium

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.